Surgical anti-adhesive starts pilot trials:
This article was originally published in Clinica
Gliatech, of Cleveland, Ohio, plans to begin pilot FDA approved trials in humans of its ADCON-A anti-adhesion product ADCON-A is a resorbable, carbohydrate polymer liquid that covers the upper peritoneal cavity and is designed to prevent scarring and adhesions following certain abdominal and colorectal surgeries. The company is developing a range of surgical anti-adhesion products based on the ADCON platform but only one, ADCON-L, for lumbar surgery, is available in the US.
You may also be interested in...
Cilta-cel maintained high response rates in longer-term multiple myeloma data, but ide-cel causes less cytokine release syndrome and severe neurotoxicity – and it has a March decision date at the US FDA.
Our updated graphic tracker of key developments from the leading vaccine candidates.
Pathway open for drug as post-covalent BTK option as Loxo gears up for "risky" Phase III head-to-head study in Q1 2021.